XHKG6669
Market cap240mUSD
Dec 23, Last price
6.24HKD
1D
0.16%
1Q
-15.22%
IPO
-66.91%
Name
Acotec Scientific Holdings Ltd
Chart & Performance
P/E
121.02
P/S
3.70
EPS
0.05
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
474m
+19.80%
Net income
14m
-79.35%
CFO
-13m
L-81.26%
Profile
Acotec Scientific Holdings Limited, a medical device company, researches and develops percutaneous transluminal angioplasty and drug-coated balloon products for the treatment of vascular diseases in Mailand China, Europe, and internationally. It offers AcoArt Orchid & Dhalia to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease; under clinical studies in nephrology for arteriovenous fistula stenosis and in neurology for vertebral atherosclerotic stenosis indications/applications; and under clinical studies in andrology for vasculogenic erectile dysfunction indications/applications. The company also provides AcoArt Tulip & Litos, which is under registration process in China and Europe, and under preclinical studies in the United States in vascular surgery for below-the-knee artery disease indications/applications; and in pre-clinical studies in andrology for vasculogenic erectile dysfunction indications/applications. The company was incorporated in 2020 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited is a subsidiary of CA Medtech Investment (Cayman) Limited.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 473,848 19.80% | 395,545 30.19% | 303,813 56.62% | ||
Cost of revenue | 467,824 | 403,495 | 337,183 | ||
Unusual Expense (Income) | |||||
NOPBT | 6,024 | (7,950) | (33,370) | ||
NOPBT Margin | 1.27% | ||||
Operating Taxes | (35) | 177 | 11,834 | ||
Tax Rate | |||||
NOPAT | 6,059 | (8,127) | (45,204) | ||
Net income | 14,487 -79.35% | 70,142 -188.70% | (79,077) 78.54% | ||
Dividends | (323,085) | ||||
Dividend yield | 11.46% | ||||
Proceeds from repurchase of equity | (33,120) | 1,431,217 | |||
BB yield | 0.64% | -50.79% | |||
| Debt | |||||
Debt current | 35,938 | 12,263 | 12,806 | ||
Long-term debt | 422,056 | 83,305 | 30,336 | ||
Deferred revenue | (260) | (295) | |||
Other long-term liabilities | 260 | 295 | |||
Net debt | (210,839) | (913,697) | (1,094,042) | ||
| Cash flow | |||||
Cash from operating activities | (12,883) | (68,755) | (10,478) | ||
CAPEX | (79,600) | (46,696) | (21,238) | ||
Cash from investing activities | (319,216) | (49,170) | (20,476) | ||
Cash from financing activities | (23,207) | (32,866) | 1,024,102 | ||
FCF | (309,467) | (223,404) | (248,575) | ||
| Balance | |||||
Cash | 879,208 | 986,455 | 1,137,184 | ||
Long term investments | (210,375) | 22,810 | |||
Excess cash | 645,141 | 989,488 | 1,121,993 | ||
Stockholders' equity | (184,186) | (93,989) | (162,884) | ||
Invested Capital | 1,714,711 | 1,403,025 | 1,380,557 | ||
ROIC | 0.39% | ||||
ROCE | 0.39% | ||||
| EV | |||||
Common stock shares outstanding | 301,078 | 299,612 | 248,065 | ||
Price | 11.28 -34.34% | 17.18 51.23% | 11.36 | ||
Market cap | 3,396,158 -34.02% | 5,147,326 82.66% | 2,818,022 | ||
EV | 3,185,319 | 4,233,629 | 1,723,980 | ||
EBITDA | 52,282 | 11,490 | (23,661) | ||
EV/EBITDA | 60.93 | 368.46 | |||
Interest | 9,833 | 1,415 | 3,824 | ||
Interest/NOPBT | 163.23% | ||||